KN-92 phosphate
Based on 11 publication(s) in Google Scholar
KN-92 phosphate is an inactive derivative of KN-93, without CaM kinase inhibitory activity. KN-92 phosphate is intended to be used as a control compound in studies designed to elucidate the antagonist activities of KN-93. KN-93 is a cell-permeable, reversible and competitive CaMKII inhibitor.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.68%
- CAS No.: 1135280-28-2
- Formule: C24H28ClN2O7PS
- Masse moléculaire:554.98
-
Stockage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Neuronal Signaling Compound Library
HY-L013
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) KN-92 phosphate
More- Nat Metab. 2020 Sep;2(9):918-933. [Abstract]
- Br J Anaesth. 2026 Jan 27:S0007-0912(25)00893-1. [Abstract]
- Curr Biol. 2026 May 4;36(9):2367-2381.e9. [Abstract]
- Brain Behav Immun. 2026 Mar 6:135:106529. [Abstract]
- Commun Biol. 2025 Mar 12;8(1):417. [Abstract]
- J Endocrinol. 2018 Mar;236(3):151-165. [Abstract]
- Sci Rep. 2023 Dec 7;13(1):21712. [Abstract]
- J Mol Cell Cardiol. 2022 Mar:164:110-125. [Abstract]
- Cell Calcium. 2021 Dec:100:102483. [Abstract]
- Proteomics. 2026 May;26(5):69-85. [Abstract]
- UCSF. 2025.
Activité biologique
KN-93 (5-50 μM; 24 hours) inhibits LX-2 cell growth and KN-92 (5-50μM; 24 hours) is ineffective in blocking cell growth[2].
The analysis of cell cycle regulator expression reveals that KN-93 rather than KN-92 reduced the expression of p53 and p21[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human hepatic stellate cells (LX-2)
-
Concentration:5-50 μM
-
Incubation Time:24 hours
-
Result:Ineffective in blocking cell growth.
Chemical Information
-
CAS No. 1135280-28-2
-
Appearance Solid
-
Masse moléculaire 554.98
-
Formule C24H28ClN2O7PS
-
Color White to off-white
-
SMILES
O=S(C1=CC=C(OC)C=C1)(NC2=CC=CC=C2CN(C/C=C/C3=CC=C(Cl)C=C3)C)=O.O=P(O)(O)O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Nat Metab
AMPK controls the axonal regenerative ability of dorsal root ganglia sensory neurons after spinal cord injury. [Abstract]2020 Sep;2(9):918-933. PMID: 32778834 -
Br J Anaesth
Sevoflurane alters α5β3GABAA receptor trafficking via calcium/calmodulin-dependent protein kinase II-dependent β3 subunit phosphorylation to produce cognitive impairment in aged mice. [Abstract]2026 Jan 27:S0007-0912(25)00893-1. PMID: 41605734 -
Curr Biol
2026 May 4;36(9):2367-2381.e9. PMID: 42025171 -
Brain Behav Immun
NR2B-CaMKII signaling in the dentate gyrus driven by astrocytic P2Y1Rs mediates the antidepressant effect of low-dose LPS. [Abstract]2026 Mar 6:135:106529. PMID: 41796645 -
Commun Biol
Piezo1 promotes the progression of necrotizing enterocolitis by activating the Ca2(+)/CaMKII-dependent pathway. [Abstract]2025 Mar 12;8(1):417. PMID: 40074811 -
J Endocrinol
2018 Mar;236(3):151-165. PMID: 29371236 -
Sci Rep
Hippocampal CaMKII inhibition induces reactivation-dependent amnesia for extinction memory and causes fear relapse. [Abstract]2023 Dec 7;13(1):21712. PMID: 38066022 -
J Mol Cell Cardiol
Ventricular SK2 upregulation following angiotensin II challenge: Modulation by p21-activated kinase-1. [Abstract]2022 Mar:164:110-125. PMID: 34774547 -
Cell Calcium
Activation of transient receptor potential vanilloid 4 exacerbates myocardial ischemia-reperfusion injury via JNK-CaMKII phosphorylation pathway in isolated mice hearts. [Abstract]2021 Dec:100:102483. PMID: 34628110 -
Proteomics
Dynamic Phosphoproteomic Profiling Captured Early Signaling Events for Cold Acclimation in Larval Zebrafish. [Abstract]2026 May;26(5):69-85. PMID: 41906457 -
Solvant et solubilité
DMSO : 50 mg/mL (90.09 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.50 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (278 KB)
-
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Smyth JT, et al. Inhibition of the inositol trisphosphate receptor of mouse eggs and A7r5 cells by KN-93 via a mechanism unrelated to Ca2+/calmodulin-dependent protein kinase II antagonism. J Biol Chem. 2002;277(38):35061-35070. [Content Brief]
[2]. An P, et al. KN-93, a specific inhibitor of CaMKII inhibits human hepatic stellate cell proliferation in vitro. World J Gastroenterol. 2007;13(9):1445-1448. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8019 mL | 9.0093 mL | 18.0187 mL | 45.0467 mL |
| 5 mM | 0.3604 mL | 1.8019 mL | 3.6037 mL | 9.0093 mL | |
| 10 mM | 0.1802 mL | 0.9009 mL | 1.8019 mL | 4.5047 mL | |
| 15 mM | 0.1201 mL | 0.6006 mL | 1.2012 mL | 3.0031 mL | |
| 20 mM | 0.0901 mL | 0.4505 mL | 0.9009 mL | 2.2523 mL | |
| 25 mM | 0.0721 mL | 0.3604 mL | 0.7207 mL | 1.8019 mL | |
| 30 mM | 0.0601 mL | 0.3003 mL | 0.6006 mL | 1.5016 mL | |
| 40 mM | 0.0450 mL | 0.2252 mL | 0.4505 mL | 1.1262 mL | |
| 50 mM | 0.0360 mL | 0.1802 mL | 0.3604 mL | 0.9009 mL | |
| 60 mM | 0.0300 mL | 0.1502 mL | 0.3003 mL | 0.7508 mL | |
| 80 mM | 0.0225 mL | 0.1126 mL | 0.2252 mL | 0.5631 mL |
KN-92 phosphate Related Classifications
HY-15517A Related Classifications
Powered by Bioz